PP2A

PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers

Retrieved on: 
Donnerstag, April 25, 2024
Phases of clinical research, Paclitaxel, Cell, Safety, Pharmacokinetics, Drug development, PP2A, Apoptosis, Index, Conference, PDAC, MTD, Patient, Principal, OC, AACR, Curie Institute (Paris), Pharmaceutical industry

PEP-010 is a pro-apoptotic agent which has demonstrated a good safety and tolerability profile and first signals of efficacy in the CLEVer-PEPtide Phase Ia dose escalation clinical trial.

Key Points: 
  • PEP-010 is a pro-apoptotic agent which has demonstrated a good safety and tolerability profile and first signals of efficacy in the CLEVer-PEPtide Phase Ia dose escalation clinical trial.
  • Four sites in France are currently recruiting: Institut Curie, Gustave Roussy, Centre François Baclesse and Institut de Cancérologie de l'Ouest.
  • “We are thrilled to see the first patients dosed in this Phase Ib trial.
  • Christophe Le Tourneau, Medical Oncologist at Institut Curie, Head of the Department of Drug Development and Innovation (D3i), and Principal Investigator of the CLEVer-PEPtide trial.

Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research

Retrieved on: 
Dienstag, Februar 27, 2024
Head, Doctor of Philosophy, Aggression, Utrecht University, PP2A, Patient, Netherlands Cancer Institute, Pharmaceutical industry

PASADENA, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced that René Bernards, PhD, professor of molecular carcinogenesis at Utrecht University in Amsterdam and head of molecular carcinogenesis at the Netherlands Cancer Institute, will present new pre-clinical data on LIXTE’s lead compound, LB-100, at the Joint Conference of European and American Associations for Cancer Research this week in Dublin, Ireland. Dr. Bernards is also a member of LIXTE’s Board of Directors.

Key Points: 
  • Dr. Bernards is also a member of LIXTE’s Board of Directors.
  • In his presentation, “Unexpected, but Highly Synergistic Combinations for Cancer Therapy,” Dr. Bernards will present data on how stress imposed onto colon cancer cells by LB-100 drives cancer cells to evolve to less cancerous behavior.
  • “The findings underscore the unique and what we believe to be exciting features and mechanism of action of LIXTE’s PP2A inhibitor, LB-100,” said Dr. James Miser, LIXTE’s Chief Medical Officer.
  • “While conventional cancer drugs aim to inhibit oncogenic signaling, which tends to drive cancer cells into more aggressive behavior, LB-100 does exactly the opposite, overloading oncogenic signaling, and thereby forcing cells to downregulate the signals that are characteristic for cancer cells.

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Retrieved on: 
Montag, Februar 26, 2024
NINDS, NCI, Immunotherapy, NIH, National Cancer Institute, Radiation, PP2A, Patent, Patient, CRADA, Development, DSM-IV codes, Research, Cancer, Pharmaceutical industry

PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).

Key Points: 
  • PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).
  • The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
  • The agreement reinforces our dedication to pioneering research and delivering innovative solutions to patients battling cancer," he added.
  • The licensed patent rights provide LIXTE with a unique opportunity to explore and develop novel combination therapies that can potentially transform the landscape of cancer treatment.

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Retrieved on: 
Montag, November 13, 2023
Doxorubicin, Squamous-cell carcinoma, Research, Netherlands Cancer Institute, City, Progression-free survival, Sarcoma, BioRxiv, Clinical trial, Patient, Northwestern, MD Anderson Cancer Center, GEIS, Monroe Dunaway Anderson, GSK, PP2A, ASTS, Sarah Cannon Research Institute, SCRI, Cancer, University, Partnership, NKI, Immunotherapy, Pharmaceutical industry

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.

Key Points: 
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.
  • GSK will provide dostarlimab and financial support for the clinical trial.
  • In addition to MD Anderson, the trial also will be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
  • This trial will enroll up to 170 patients and will begin in partnership with GEIS clinical sites.

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

Retrieved on: 
Montag, Oktober 16, 2023
Cancer, NKI, Research, PP2A, Netherlands Cancer Institute, Drug combination, Immunotherapy, Patient, Pharmaceutical industry

PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers. The new agreement also will seek to find synthetic lethal combinations in additional cancer types.

Key Points: 
  • PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers.
  • The new agreement also will seek to find synthetic lethal combinations in additional cancer types.
  • NKI, based in Amsterdam, Netherlands, is among the world’s leading comprehensive cancer centers.
  • Oncode Institute, headquartered in Utrecht, Netherlands, is a major independent cancer research center dedicated to translating research into practice and bringing discoveries into a clinic setting more quickly.

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

Retrieved on: 
Montag, Oktober 9, 2023
Bureau of Oceans and International Environmental and Scientific Affairs, City of Hope National Medical Center, Mayo Clinic, Family, College, College of Physicians & Surgeons of Mumbai, Breast cancer, Medicine, PP2A, Cancer, Toxicity, Molecular epidemiology, Columbia University, City, AOA, NCI, Princeton University, Pharmacology, Patient, Surgeon, Pharmaceutical industry, Management

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its founder and Executive Chairman, John S. Kovach, M.D.

Key Points: 
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its founder and Executive Chairman, John S. Kovach, M.D.
  • Dr. Kovach, 87, founded the Company in 2005 and held a distinguished medical and scientific career that focused on the causation and treatment of cancer.
  • Dr. Kovach served as LIXTE’s President and Chief Executive Officer from 2005 through September 26, 2023.
  • In connection with the Company’s management succession plan, Dr. Kovach was succeeded as President and Chief Executive Officer by Bas van der Baan on that date.

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Retrieved on: 
Dienstag, September 26, 2023
DNA, Business development, Vice, PP2A, Immunotherapy, Patient, Cytokine, DNA repair, Pharmaceutical industry

PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE’S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 and was named Executive Chairman. Dr. Kovach will continue as the Company’s Chief Scientific Officer. Both Dr. Kovach and Mr. van der Baan will continue in their roles as members of the Board of Directors of LIXTE.

Key Points: 
  • Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise;
    PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc .
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023.
  • Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 and was named Executive Chairman.
  • Both Dr. Kovach and Mr. van der Baan will continue in their roles as members of the Board of Directors of LIXTE.

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

Retrieved on: 
Mittwoch, September 20, 2023
Mohamed Jazaeri, GSK, OCCC, Obstetrics, Children's Art Project at The University of Texas MD Anderson Cancer Center, Survival, Clinical trial, Gynecologic Oncology (journal), DRS, Monroe Dunaway Anderson, Immunotherapy, Feinberg School of Medicine, Assistant, Squamous-cell carcinoma, Patient, Anderson, University, Gynaecology, Observation, PD-1, MPH, MD Anderson Cancer Center, Clinical, Northwestern, Pharmaceutical industry, PP2A, John Hinchcliff, MD

PASADENA, CA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE”), today announced a Phase 1b collaborative clinical trial to assess whether adding Lixte’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC). The clinical trial is sponsored by The University of Texas - MD Anderson Cancer Center and will be conducted at MD Anderson and will also be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center. LIXTE will provide LB-100; GSK will provide dostarlimab and financial support for the clinical trial.

Key Points: 
  • The clinical trial is sponsored by The University of Texas - MD Anderson Cancer Center and will be conducted at MD Anderson and will also be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
  • LIXTE will provide LB-100; GSK will provide dostarlimab and financial support for the clinical trial.
  • The clinical trial is based on the observation of longer survival of patients with OCCC treated with immunotherapy whose cancer cells have an acquired gene mutation resulting in a reduction in PP2A.
  • This clinical trial is an exciting alternative approach that leverages the potential synergy between these two agents and is aiming to improve the impact immunotherapy may have for these patients.”

Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy

Retrieved on: 
Montag, Juli 17, 2023
DNA, PP2A, Netherlands Cancer Institute, Research, Cell, Antibody, Immunotherapy, Messenger, Protein, Radiation, DNA repair, Immune system, Phosphorylation, Pharmaceutical industry, Vaccine, BioRxiv, Cancer

PASADENA, CA, July 17, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW) today announced that a recently posted article in BioRxiv (https://www.biorxiv.org/content/10.1101/2023.07.12.548685v1), based on the results of a collaboration between the Company and the Netherlands Cancer Institute, shows that inhibition of PP2A in colon cancer cells, using LIXTE’s lead clinical compound LB-100, leads to major changes in the way cancer cells process their mRNAs.

Key Points: 
  • Based on this finding, cancer cells are predicted to produce a significant number of aberrant proteins that can be recognized by the immune system.
  • John S. Kovach, M.D., CEO and Founder of LIXTE, said, “The case for combining LB-100 with immunotherapy is based on extensive pre-clinical data.
  • This finding concurs with multiple pre-clinical studies demonstrating synergy between LB-100 and radiotherapy or different chemotherapies in various cancer models.
  • That LB-100 has such an unexpectedly strong effect on mRNA splicing is a nice surprise that further supports its use in combination with immunotherapy.”

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

Retrieved on: 
Mittwoch, Juni 7, 2023
PP2A, Clinical trial, Biomarker, Teaching hospital, Sarcoma, MD, Patient, ASTS, Doxorubicin, Pharmaceutical industry

Once the dose is determined, a randomized Phase 2 study will be initiated seeking to gain evidence that the inclusion of doxorubicin increases time to a progression and/or overall survival of patients with advanced soft tissue sarcomas (ASTS).

Key Points: 
  • Once the dose is determined, a randomized Phase 2 study will be initiated seeking to gain evidence that the inclusion of doxorubicin increases time to a progression and/or overall survival of patients with advanced soft tissue sarcomas (ASTS).
  • The Phase 1b part is starting now, while deep investigations are being developed to search the most robust predictive biomarkers for LB-100 activity in the sarcoma context.
  • Investigators of this trial are excited and hopeful, with the idea of potentially improving the efficacy exhibited by doxorubicin alone during its solo 40-year reign.
  • We have 3 activated sites in Spain right now and 3 additional sites will join the Phase 1b part in the coming weeks.”